Compare AngloGold Ashanti Limited (AU) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Pfizer Inc — how do they compare? AngloGold Ashanti Limited trades at $99.25 (market cap $49.28B), while Pfizer Inc trades at $26.37 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 3.1× AngloGold Ashanti Limited's market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.
| AU | PFE | |
|---|---|---|
Market Cap | $49.28B | $151.73B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $28.56 |
52-Week Low | $52.15 | $23.60 |
Enterprise Value | $48.29B | $203.22B |
Dividend Yield | 4.64% | 6.46% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $97.25, up 1.07% today, with a bullish technical signal from moving averages but overbought RSI readings. Strong fundamentals include a 26.64% net margin for 2025, robust free cash flow growth, and a $2 billion buyback program. Recent Q2 2026 earnings beat expectations, though Q4 2025 and Q2 2026 were misses. Analyst consensus is bullish with a $120.33 price target, and institutional buying has been noted in recent filings.
Outlook remains positive due to high gold prices, production growth, and shareholder returns, but risks include operational disruptions, inflation pressures, and volatile gold markets. The stock offers value with a P/E of 13.06 and strong profitability, yet investors should monitor cost inflation and geopolitical factors affecting mining operations.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
